期刊
SPRINGERPLUS
卷 2, 期 -, 页码 -出版社
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1186/2193-1801-2-126
关键词
Anastrozole; Ginkgo biloba; Herb-drug interaction; Letrozole; Tamoxifen
资金
- American Society of Clinical Oncology (ASCO) Career Development Award
- National Institute of Complementary Medicine project grant
- Cancer Institute NSW Clinical Research Fellowship
- National Health and Medical Research Council PhD Scholarship
- National Breast Cancer Foundation [PD-12-04] Funding Source: researchfish
Women receiving treatment for breast cancer commonly ingest herbal medicines. Little is known about the potential for herb-drug interactions in this population. The aim of this study is to investigate the effect of ginkgo biloba co-administration on the pharmacokinetics of tamoxifen, anastrozole and letrozole. This was a prospective open-label cross-over study in 60 women with early stage breast cancer taking either tamoxifen, anastrozole or letrozole (n=20/group). Participants received ginkgo biloba (EGb 761) for 3 weeks (120 mg twice daily). Trough concentrations of drugs were measured before and after ginkgo biloba treatment using LC-MS/MS. Toxicities were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events. Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 +/- 29.0, 86.5 +/- 25.3 ng/mL; p=0.16), letrozole (91.1 +/- 50.4, 89.6 +/- 52.14 ng/mL; p=0.60) or anastrozole (29.1 +/- 8.6, 29.1 +/- 7.6 ng/mL; p=0.97). Ginkgo biloba was well tolerated, with no difference in toxicity during ginkgo biloba. Co-administration of ginkgo biloba does not significantly affect the pharmacokinetics of tamoxifen, anastrozole or letrozole. There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据